Eli Lilly (LLY) acquires Centessa for up to $7.8 billion
Published on 3/31/2026
AI Summary
Eli Lilly (LLY) announced its acquisition of Centessa Pharmaceuticals in a deal valued up to $7.8 billion, aiming to diversify into sleep disorder treatments. Centessa's lead therapy targets excessive daytime sleepiness and is currently in mid-stage studies. Lilly's offer includes $38 per share in cash, a 37.8% premium, and a contingent value right worth about $1.5 billion. Centessa's shares rose 46% in premarket trading following the announcement, which is set to close in the third quarter.
Related News
M&A
Columbia Financial (CLBK) Enters Agreement with KBW for Stock Offering
May 15
M&A
Phillips Edison (PECO) Appoints Dan Sutherland as VP of Acquisitions
May 15
M&A
Profusa (PROF) Transitions to Nasdaq Capital Market for Compliance
May 15
M&A
Trump Xi Summit Leads to Potential Boeing Orders, No Major Deals
May 15